Hosokawa T, Howard R B, Maguire M H
Br J Pharmacol. 1985 Jan;84(1):237-41.
Pressor effects of angiotensin I (AI) and angiotensin II (AII) on the human foetoplacental vasculature were compared in dual-perfused term placental cotyledons in which foetoplacental perfusion pressure was monitored. Arterial injections of 1 nmol doses of AI and AII caused marked increases in perfusion pressure; the mean pressor response to AI was 92.9 +/- 5.8% (mean +/- s.e. mean) of the AII response. The angiotensin-converting enzyme inhibitor captopril at 2.2 microM reversibly reduced the AI response to 13.7 +/- 3.2% (mean +/- s.e. mean) of the AII response, which was unaffected. Saralasin, an AII receptor blocker, at 94 nM reversibly antagonized both AI-and AII-induced increases in foetoplacental perfusion pressure. It is concluded that foetoplacental vasoconstriction elicited by AI is due to its conversion to AII by angiotensin-converting enzyme present in the foetoplacental bed.
在监测胎儿 - 胎盘灌注压力的双灌注足月胎盘小叶中,比较了血管紧张素I(AI)和血管紧张素II(AII)对人胎儿 - 胎盘血管系统的升压作用。动脉注射1 nmol剂量的AI和AII导致灌注压力显著升高;AI的平均升压反应为AII反应的92.9±5.8%(平均值±标准误)。2.2 μM的血管紧张素转换酶抑制剂卡托普利可将AI反应可逆地降低至AII反应的13.7±3.2%(平均值±标准误),而AII反应不受影响。94 nM的AII受体阻滞剂沙拉新可可逆地拮抗AI和AII诱导的胎儿 - 胎盘灌注压力升高。结论是,AI引起的胎儿 - 胎盘血管收缩是由于其在胎儿 - 胎盘床中存在的血管紧张素转换酶作用下转化为AII所致。